Outcomes of Transplantation with Related- and Unrelated-Donor Stem Cells in Children with Severe Thalassemia  by Hongeng, Suradej et al.
O
U
S
I
f
c
e
(
F
t
m
t
s
B
i
[
a
Biology of Blood and Marrow Transplantation 12:683-687 (2006)
 2006 American Society for Blood and Marrow Transplantation
1083-8791/06/1206-0011$32.00/0
doi:10.1016/j.bbmt.2006.02.008
Butcomes of Transplantation with Related- and
nrelated-Donor Stem Cells in Children with
evere Thalassemia
Suradej Hongeng,1,5 Samart Pakakasama,1,5 Ampaiwan Chuansumrit,1 Nongnuch Sirachainan,1,5
Pimpan Kitpoka,2 Umaporn Udomsubpayakul,4 Artit Ungkanont,3,5 Saengsuree Jootar3,5
Departments of 1Pediatrics, 2Pathology, and 3Internal Medicine, 4Research Center, and 5Bone Marrow
Transplantation Program, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
Correspondence and reprint requests: Suradej Hongeng, MD, Department of Pediatrics, Faculty of Medicine,
Ramathibodi Hospital, Rama VI Road, Bangkok 10400, Thailand (e-mail: rashe@mahidol.ac.th).
Received November 8, 2005; accepted February 13, 2006
ABSTRACT
Recently published reports indicate that the outcome of unrelated donor transplantations in patients with
leukemia is currently comparable to that of transplantation from identical family donors. We investigated the
possibly favorable outcomes of related and unrelated transplantation in children with severe thalassemia. We
reviewed transplantation outcome in 49 consecutive children with severe thalassemia who underwent alloge-
neic stem cell transplantation with related-donor (n  28) and unrelated-donor (n  21) stem cells between
September 1992 and May 2005 at the Faculty of Medicine, Ramathibodi Hospital, Mahidol University
(Bangkok, Thailand). Analysis of engraftment, frequency of procedure-related complications, and thalassemia-
free survival showed no advantage from use of related-donor stem cells. The 2-year thalassemia-free survival
estimate for recipients of related-donor stem cells was 82% compared with 71% in the unrelated-donor stem
cell group (P  .42). The present study provides evidence to support the view that it is quite reasonable to
consider unrelated-donor stem cell transplantation an acceptable therapeutic approach in severe thalassemia,
at least for patients who are not fully compliant with conventional treatment and do not yet show irreversible
severe complications of iron overload.
© 2006 American Society for Blood and Marrow Transplantation
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sNTRODUCTION
Allogeneic bone marrow transplantation (BMT)
rom a genotypically identical family donor is the only
urative therapy for patients with thalassemia. How-
ver, the probability of ﬁnding a histocompatibility
HLA)-identical donor within the family is 30%.
or patients with thalassemia without an HLA-iden-
ical sibling donor, there was until recently no treat-
ent other than chronic transfusion and iron chela-
ion. Within the past few years, there has been a
teady increase in the number of unrelated-donor
MTs in a variety of disorders, mainly due to the
ncrease in the number of volunteer donors worldwide
1]. There are only 2 case-series reports, by La Nasa et
l. [2] from Italy and Hongeng et al. [3] from Thai- 1
B&MTand, that are available about unrelated BMT in
halassemia and both series have indicated favorable
utcomes. The present study investigated outcomes of
elated and unrelated stem cell transplantations
SCTs) and whether these compare favorably in chil-
ren with severe thalassemia that was treated at a
ingle institution (Ramathibodi Hospital, Mahidol
niversity, Bangkok, Thailand).
ETHODS
We studied 49 consecutive patients who received
elated-donor (n  28) or unrelated-donor (n  21)
tem cells for severe thalassemia between September
992 and May 2005. Some of the present patients
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6ere previously reported [3-5]. Patients and donors or
heir parents signed an informed consent before treat-
ent. Characteristics of the 2 groups are presented in
able 1. Some of our patients could not be classiﬁed
ith the Pesaro risk classiﬁcation because we did not
able 1. Characteristics of Patients, Frequencies of GVHD,
rocedure-Related Complications, and Causes of Death
n Related- and Unrelated-donor SCT*
Related
(n  28)
Unrelated
(n  21)
edian age at transplantation,
y (range) 7.2 (0.5-18.7) 4.0 (0.7-12.0)
ale/female 13/15 14/7
ype of thalassemia
/ thalassemia 8 8
 thalassemia/hemoglobin E 20 13
ucarelli class
1 15 13
2/3 13 8
ource of stem cells
Bone marrow 12 21
Peripheral blood 12 —
Cord blood 4 —
LA matching
6/6 HLA antigen match 23 —
5/6 HLA antigen match 3 —
4/6 HLA antigen match 2 —
6/6 HLA allele match — 13
5/6 HLA allele match — 6
4/6 HLA allele match — 2
yeloablative
Bu 16 Cy 200† 20 —
Bu 16 Cy 200 ATG 40‡ 4 21
onmyeloablative
Bu 8 Flu 175 ATG 20 TLI 500
cGy§ 4 —
VHD
Acute, grade II-IV 9 (32%) 9 (42%)
Acute, grade III-IV 3 (11%) 3 (14%)
Chronic 4 (14%) 3 (14%)
Extensive chronic 2 (7%) 1 (4%)
rocedure-related complications
Hemorrhagic cystitis 3 (11%) 4 (19%)
Sepsis 3 (11%) 3 (14%)
Autoimmune hemolytic anemia — 1 (4%)
Seizure 2 (7%) 4 (19%)
Veno-occlusive disease 6 (22%) 5 (23%)
auses of death
Graft failure 1 —
Bleeding — 1
Pneumonitis — 1
Sepsis 1 —
Chronic GVHD — 1
edian follow-up, mo (range) 51 (6-157) 35 (6-55)
No statistical comparison showed signiﬁcant differences in inci-
dence of acute and chronic GVHD and procedure-related com-
plications.
Busulfan 16 mg/kg, cyclophosphamide 200 mg/kg.
Busulfan 16 mg/kg, cyclophosphamide 200 mg/kg, antithymocyte
gloubulin 40 mg/kg.
Busulfan 8 mg/kg, ﬂudarabine 175 mg/m2, antithymocyte gloubu-
lin 20 mg/kg, total lymphoid irradiation 500 cGy.erform routine pretransplantation liver biopsy before c
84000 [6]. Although some of our patients did not have
retransplantation liver biopsy, these patients had se-
ere anemia, marked hepatosplenomegaly, multiple
lood transfusions, and high serum ferritin levels.
ost of them received no or inadequate iron-chela-
ion therapy. Therefore, these patients were classiﬁed
s moderate to high risk (Lucarelli class 2 or 3) [6].
istocompatibility
HLA was determined by conventional serologic typ-
ng for class I and II antigens. DNA typing with high-
esolution sequence-speciﬁc oligonucleotide probes
or class I and II loci was undertaken for patients with
atched and mismatched HLA-unrelated or mis-
atched HLA-related donors.
onditioning Regimen
Forty-ﬁve patients received myeloablative and 4
atients received nonmyeloablative conditioning reg-
men. A myeloablative regimen consisted of busulfan 1
g/kg taken every 6 h for 4 days, and cyclophospha-
ide 50 mg/kg infused daily for 4 days. Antilympho-
yte globulin (ATG; Fresenius, Graefelﬁng, Ger-
any) 10 mg/kg/d was also infused daily for 4 days in
atients with unrelated BMT and cord blood trans-
lantation. A nonmyeloablative regimen consisted of
usulfan 1 mg/kg taken every 6 hours for 2 days,
udarabine 35 mg/m2 infused daily for 5 days, ATG 5
g/kg/d infused daily for 4 days, and total lymphoid
rradiation administered at a single fraction of 500
Gy [4,5]. The nonmyeloablative regimen was de-
igned for patients who were classiﬁed as having Lu-
arelli class 3 and received stem cells from matched or
ismatched related donors. All patients in risk class 3
ere given hydroxyurea 20 mg/kg/d 3 months be-
ore BMT to decrease erythroid expansion and thus
revent graft rejection [3-5].
reparation of Stem Cell Grafts
T-cell nondepleted bone marrow, peripheral
lood, or cord blood stem cell graft was infused on day
. Only 1 patient who underwent nonmyeloablative
CT received puriﬁed CD34 cells that were derived
rom 2 antigens and HLA-mismatched maternal pe-
ipheral blood stem cells with additional CD3 cells
o a total of 1 105 CD3 cells/kg [5]. These puriﬁed
D34 cells were obtained with Clinimacs (Miltenyi,
ergisch, Germany). For peripheral blood stem cell
raft preparation, donors received subcutaneous gran-
locyte colony-stimulating factor 10 g/kg/d for 4
ays before leukapheresis procedures.
raft-versus-Host Disease
For graft-versus-host disease (GVHD) prophy-
axis, 2 to 4 days before transplantation, patients re-
eived cyclosporin at a dose that was adjusted to
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Bchieve a plasma concentration of 250-350 ng/mL or
acrolimus at a dose that was adjusted to achieve a
lasma concentration of 5-15 ng/mL. All received a
hort course of methotrexate [7] except patients who
nderwent cord blood transplantation; these patients
eceived methylprednisolone 1-2 mg/kg/d for 28 days.
f GVHD remained at grade II for 7 days or pro-
ressed, the steroid dose was increased to 5-10 mg/
g/d. If there was further deterioration or no evidence
f improvement after 5 days of high-dose steroid ther-
py, patients were treated with daclizumab (interleu-
in 2 receptor antagonist) [8] or inﬂiximab (tumor
ecrotic factor antagonist) [9]. Two patients also re-
eived third-party parental mesenchymal stem cells
or refractory GVHD, even though they received da-
lizumab or inﬂiximab and their GVHD did not re-
pond to those agents [10].
ngraftment Criteria
Three consecutive days with an absolute neutro-
hil count .5  109/L or 7 consecutive days with a
latelet count 20  109/L without transfusion were
aken as evidence of engraftment.
nfectious Diseases
Preventive treatment for Pneumocystis carinii pneu-
onia consisted of trimethoprim-sulfamethoxazole
cotrimoxazole) at 5 mg/kg/d divided into 2 doses for
days a week. Cytomegalovirus (CMV) and Ebstein-
arr virus (EBV) reactivations were monitored by
MV and EBV viral loads. Patients with a CMV viral
oad 103 copies/mL were treated with ganciclovir
11] and intravenous immunoglobulin [11] and pa-
ients with an EBV viral load 103 copies/mL were
reated with rituximab [12].
onitoring of Chimerism
Chimerism was documented by in situ Y0chro-
osome hybridization of bone marrow or blood
amples in sex-mismatched donor/recipient pairs, by
nalysis of a variable number of tandem repeat poly-
orphism, and by microsatellite analysis of blood
amples in the case of sex-matched pairs.
erformance Activity
The performance test with the Lansky or Karnof-
ky scale was assessed at 1 year by the attending
hysicians.
tatistics
Continuous variables, such as age and time, to
yeloid and platelet engraftment were compared by
he Student t test. Categorical variables, such as sex,
requency of acute and chronic GVHD, and other
ost-transplant complications, were compared by chi- c
B&MTquare test or the Fisher exact test. Survival probabil-
ty was estimated by the Kaplan-Meier product-limit
ethod.
ESULTS
Patients in the 2 groups were slightly different in
ge and sex. Median ages at transplantation were 4
ears in the unrelated group and 7.2 years in the
elated group, and more female patients were included
n the related group (Table 1). Because we did not
erform liver biopsy before transplantation before
000, we classiﬁed patients who had 1 Lucarelli risk
actor as Lucarelli class 2/3. Of the 28 patients who
eceived stem cells from a related donor, 23 had a 6/6
LA antigen match, 3 had a 5/6 HLA antigen match,
nd 2 had a 4/6 HLA antigen match. Of the 21
atients who received marrow from an unrelated do-
or, 13 had a 6/6 HLA allele match, 6 had a 5/6 HLA
llele match, and 2 had a 4/6 HLA allele match by
olecular typing.
In the related group, 12 of 28 patients received
tem cells from bone marrow, 12 from peripheral
lood, and 4 from cord blood; in the unrelated group,
ll 21 patients received stem cells from bone marrow.
The course of transplantation in patients who re-
eived grafts from an unrelated donor did not differ
ubstantially from that in the related group. Mean
imes to myeloid cell engraftment were identical (16
ays; ranges, 12-35 and 11-30, respectively), although
latelet engraftment was delayed in recipients of un-
elated-donor stem cells (mean, 50 days; range, 20-
50; versus 25 day; range, 15-75; P  .01). Frequen-
ies of GVHD were similar, as were frequencies for
ther post-transplantation complications (Table 1).
ecause we administered preemptive therapy for
MV and EBV infections by CMV and EBV viral
oad monitoring, there was no incidence of CMV
isease and EBV post-transplant lymphoproliferative
isease in our study. Karnofsky or Lansky perfor-
ances in patients who survived 1 year were similar
related-donor group: mean, 98; range, 85-100; in
nrelated-donor group: mean, 95; range, 80-100).
For the ﬁrst transplantation, the 2-year thalasse-
ia-free survival rate for the 49 patients with thalas-
emia was 77% (95% conﬁdence interval, 61-86) and
verall survival rate was 89% (95% conﬁdence inter-
al, 72-94). The 2-year thalassemia-free survival rate
stimated for recipients in the related-donor group
as 82% (95% conﬁdence interval, 61-92) com-
ared with 71% (95% conﬁdence interval, 45-85) in
he unrelated-donor group (P  .42; Figure 1). The
-year overall survival rate estimated for recipients
n the related-donor group was 92% (95% conﬁ-
ence interval, 70-97) compared with 82% (95%
onﬁdence interval, 53-94) in the unrelated-donor
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6roup (P .43; Figure 2). The rejection rate after ﬁrst
ransplantation in the related-donor (n  4) and un-
elated-donor (n  3) groups was the same (14%). Of
patients in the related group whose graft failed after
he ﬁrst transplantation, 2 underwent a second trans-
lantation with stem cells from the same donors and
chieved successful engraftment with full (100%) do-
or chimerism; the second myeloablative regimen
onsisted of busulfan 1 mg/kg for 4 days, cyclophos-
hamide 50 mg/kg for 4 days, and ATG 10 mg/kg/d
or 4 days; 1 patient died of graft failure; and 1
waits a second transplantation. Three patients in
he unrelated group whose graft failed had autolo-
ous recovery and are still alive. Two patients in the
elated group and 3 in the unrelated group died
P  .63). The causes of death are listed in Table 1.
e did not analyze the survival rate after the second
ransplantation.
Four patients in the related group who underwent
onmyeloablative transplantation had full donor en-
raftment (100% donor chimerism) at 1 month, 6
onths, and 1 year after transplantation.
Of 4 patients who received cord blood stem cells,
had primary graft failure and 3 achieved full donor
himerism. One patient died of salmonella sepsis at 1
ear after transplantation, and 2 are still alive without
halassemia.
All patients in the 2 groups who were alive and
ree of thalassemia had full (100%) donor chimerism
t the time of this report. Median follow-up times
ere 51 months (range, 6-157) in the related group
nd 35 months (range, 6-55) in the unrelated group.
ISCUSSION
Most patients with thalassemia do not have an
LA-identical donor within the family. For this rea-
on, BMT centers that have been engaged in a cure for
halassemia have been under increasing pressure from
igure 1. Thalassemia-free survival analysis of related- and unre-
ated-donor transplantation groups.atients and families to explore the possibility of t
86ransplantation with alternative donors. Use of partly
atched family donors carries a high risk of rejection,
VHD, and mortality and had been conﬁned to par-
icular clinical situations [13].
Recently published reports have indicated that
utcome of unrelated-donor transplantation in pa-
ients with leukemia is currently comparable to that of
ransplantation from identical family donors. This is
ue in part to the better compatibility between donor
nd recipient afforded by DNA methods [14].
La Nasa et al [2] reported thalassemia-free sur-
ival, rejection, and mortality rates of 66%, 12.5%,
nd 19%, respectively, for 32 patients from 4 BMT
enters for a median of 30 months after unrelated-
onor BMT. In our study, 2-year thalassemia-free
urvival rates were 82% in the related group and 71%
n the unrelated group (P  .42). Median follow-up
imes were 51 months in the related group and 35
onths in the unrelated group. Our study is the ﬁrst
o support the success of unrelated-donor SCT in
halassemia as a case series that is comparable to that
ffered by a related-donor group in a single institu-
ion, even though we did not perform extended hap-
otype analysis as La Nasa et al [2] did. Apart from
latelet engraftment, which was delayed by 25 days in
he unrelated group, the end points of our study (en-
raftment, frequency of acute and chronic GVHD,
ejection rate, performance status, thalassemia-free
urvival rate, and mortality rate) were unaffected by
he donor source of stem cells.
Our previous report demonstrated a favorable out-
ome, with a 100% thalassemia-free survival rate for
he ﬁrst 11 patients who underwent unrelated-donor
CT [3]. Because there was rejection in 3 patients in
he unrelated group after the ﬁrst 11 patients had been
nrolled, we plan to add ﬂudarabine at a dose of 30
g/m2/d for 5 days with the same dose of busulfan in
he conditioning regimen to ensure an improved and
ustained engraftment of donor cells for unrelated-
onor transplantation in a future study.
igure 2. Overall survival analysis of related- and unrelated-donor
ransplantation groups.
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Related and Unrelated Donor SCT in Pediatric Severe Thalassemia
BThe present study has shown that outcomes of
elated- and unrelated-donor SCT in children with
evere thalassemia are favorably comparable. We be-
ieve the reason for this favorable result in unrelated
ransplantation patients is the younger age of this
ample. Because there were multiple differences in
atient characteristics and treatment for the 2 groups,
his study was not meant to be comparison of the same
egimen for different donors. Rather, the outcomes
how that reasonably comparable results can be
chieved. Due to the small numbers of cases, we can-
ot rule out small differences in outcomes between
roups.
The present study provides an additional evidence
o support the view that it is quite reasonable to
onsider unrelated-donor SCT as an acceptable ther-
peutic approach in thalassemia, at least for younger
atients who are not fully compliant with conven-
ional treatment and do not yet show irreversible se-
ere complications of iron overload.
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